Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials
Conclusions
The results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5 days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population.
PROSPERO registration number
CRD42022369850.
Source: BMJ Open - Category: General Medicine Authors: Cheema, H. A., Jafar, U., Shahid, A., Masood, W., Usman, M., Hermis, A. H., Naseem, M. A., Sahra, S., Sah, R., Lee, K. Y. Tags: Open access, Infectious diseases, COVID-19 Source Type: research
More News: Colchicine | Colcrys | COVID-19 | Databases & Libraries | General Medicine | Infectious Diseases | Intensive Care | Study